Creative Medical Technology Ho - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CELZ Nasdaq 8731 https://creativemedicaltechnology.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Creative Medical Technology Ho

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes - Feb 8th, 2023 1:00 pm
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes - Nov 3rd, 2022 11:30 am
Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line - Oct 20th, 2022 12:00 pm
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study - Sep 26th, 2022 12:00 pm
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study - Jul 28th, 2022 11:30 am
Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform - Jun 15th, 2022 12:30 pm
Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Apr 29th, 2022 12:40 pm
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product - Apr 20th, 2022 12:30 pm
Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World - Apr 12th, 2022 12:30 pm
Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform - Mar 31st, 2022 12:30 pm
Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study - Mar 23rd, 2022 12:30 pm
Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction - Mar 10th, 2022 1:30 pm
Creative Medical Technology to Participate in the 34th Annual Roth Conference - Mar 8th, 2022 1:30 pm
Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer - Mar 2nd, 2022 1:30 pm